Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1480

Shown on this page

Current sort

Live official records

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: VHB937, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 21
States / cities: La Jolla, California • Loma Linda, California • Los Angeles, California + 18 more

Conditions: Breast Cancer, Solid Tumors, Adult
Interventions: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 28
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more

Conditions: Diffuse Large B Cell Lymphoma
Interventions: Radiation Therapy; Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 7
States / cities: Boston, Massachusetts • Weymouth, Massachusetts • St Louis, Missouri + 3 more

Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
Interventions: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 106
States / cities: Anchorage, Alaska • Fayetteville, Arkansas • Rogers, Arkansas + 61 more

Conditions: Pulmonary Embolism
Interventions: Indigo Aspiration System; Device
Lead sponsor: Penumbra Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 58
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 48 more

Conditions: Cognitive Impairment, Dementia With Behavioral Disturbance, Dementia, Alzheimer Disease
Interventions: Enhanced home health aide training in dementia and dementia-related behaviors; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Family History of Lung Cancer
Interventions: CT scan, Sybil; Diagnostic Test · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis Lung
Interventions: 4D-710; Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 20
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more

Conditions: Platinum-resistant Ovarian Cancer
Interventions: MEN2501; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Springdale, Arkansas • New Haven, Connecticut • Sarasota, Florida + 4 more

Conditions: Infant, Extremely Premature, Obstetric Labor, Premature, Premature Birth, Intensive Care, Neonatal, Intensive Care Units, Neonatal
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 0 Years to 1 Year
Enrollment: 5,000 participants
Timeline: 2019 – 2030
U.S. locations: 43
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 30 more

Conditions: Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
Interventions: PT0511, Cetuximab; Drug
Lead sponsor: PAQ Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Boston, Massachusetts • San Antonio, Texas • West Valley City, Utah + 1 more

Conditions: Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
Interventions: OKI-219, Fulvestrant, Trastuzumab, Tucatinib, Atirmociclib, Ribociclib; Drug
Lead sponsor: OnKure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Encinitas, California • La Jolla, California • Los Angeles, California + 9 more

About this Massachusetts General Hospital institution page

What this page lists: ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Massachusetts General Hospital

Filter and sort this campus

Live official records

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System

The Care for America's Aging Study

LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol A

4D-710 in Adult Patients With Cystic Fibrosis

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

About this Massachusetts General Hospital institution page